<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prospective 1-year EPIC study enrolled 341 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>); although baseline iron burden was &gt;2500ng/mL, approximately 50% were chelation-naïve </plain></SENT>
<SENT sid="1" pm="."><plain>Overall median serum ferritin decreased significantly at 1 year (p=0.002) </plain></SENT>
<SENT sid="2" pm="."><plain>Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake </plain></SENT>
<SENT sid="3" pm="."><plain>Sustained reductions in labile plasma iron were observed </plain></SENT>
<SENT sid="4" pm="."><plain>Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported <z:chebi fb="0" ids="49005">deferasirox</z:chebi> data in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p&lt;0.0001) </plain></SENT>
<SENT sid="6" pm="."><plain>This large dataset prospectively confirms the efficacy and well characterizes the safety profile of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>